Sugi Predict

Sugi Predict / Compounds / SCHEMBL1284008

SCHEMBL1284008

SCHEMBL1284008

Brc1cccc(-c2nc3ccccc3[nH]2)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 11/20 0.67
▸ NPC1 O15118 10/20 0.67
▸ RAB9A P51151 10/20 0.67
▸ SMN1; SMN2 Q16637 10/20 0.67
▸ ALDH1A1 P00352 9/20 0.67
▸ HPGD P15428 5/20 0.67
▸ HSD17B10 Q99714 4/20 0.67
▸ TP53 P04637 3/20 0.67
▸ GAA P10253 1/20 0.66
▸ HDAC3 O15379 1/20 0.59
▸ HDAC1 Q13547 1/20 0.59
▸ HDAC2 Q92769 1/20 0.59
▸ HDAC8 Q9BY41 1/20 0.59
▸ HDAC6 Q9UBN7 1/20 0.59
▸ PKM P14618 3/20 0.58
▸ ABCB11 O95342 1/20 0.58
▸ NPSR1 Q6W5P4 1/20 0.58
▸ MAPT P10636 5/20 0.57
▸ USP2 O75604 1/20 0.57
▸ TDP1 Q9NUW8 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30038279 1.00 KDM4E (0.67) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL3417301 0.88 NPC1 (0.78) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL16050861 0.87 KDM4E (0.81) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL28775021 0.86 ALDH1A1 (0.65) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL28027557 0.86 KDM4E (0.75) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL17470481 0.83 NPC1 (0.76) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL30726509 0.81 CYP11B1 (0.62) GAAHDAC3HDAC1HDAC2HDAC8
SCHEMBL27040054 0.81 CYP11B1 (0.62) GAAHDAC3HDAC1HDAC2HDAC8
SCHEMBL2090649 0.81 HDAC3 (0.54) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL481735 0.81 NPC1 (0.72) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4559908-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF S2CBio Inc. (KR) 2025-05-28 — — EP disclosed
WO-2024058617-A1 ANTIVIRAL USE OF HETEROARYL DERIVATIVE COMPOUND 일동제약(주) 2024-03-21 — — WO disclosed
WO-2024019541-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF 일동제약(주) 2024-01-25 — — WO disclosed
WO-2024019541-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF 일동제약(주) 2024-01-25 — — WO disclosed
CN-110741002-B Heterocyclic compound and organic light-emitting device comprising same 株式会社LG化学 2023-12-05 — — CN disclosed
CN-114989094-B Method for synthesizing benzimidazole derivative by visible light catalysis 云南民族大学 2023-09-29 — — CN disclosed
CN-116635028-A Modulators of c-MYC mRNA translation and their use in the treatment of cancer 艾尼莫生物科技公司 2023-08-22 — — CN disclosed
CN-112438977-B Myricetin derivative containing benzimidazole, preparation method and application 贵州大学 2023-05-19 — — CN disclosed
CN-112194654-B Benzimidazole-containing myricetin derivative, preparation method and application 贵州大学 2022-11-08 — — CN disclosed
CN-114989094-A Method for synthesizing benzimidazole derivative by visible light catalysis 云南民族大学 2022-09-02 — — CN disclosed
US-20120088752-A1 HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF SIENA BIOTECH S.P.A. (IT) 2012-04-12 — — US disclosed
US-20120088752-A1 HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF SIENA BIOTECH S.P.A. (IT) 2012-04-12 — — US disclosed
WO-2010142426-A1 HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF SIENA BIOTECH S.P.A. (IT) 2010-12-16 — — WO disclosed
US-20100286114-A1 HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF SIENA BIOTECH S.P.A. (IT) 2010-11-11 — — US disclosed
US-20100286114-A1 HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF SIENA BIOTECH S.P.A. (IT) 2010-11-11 — — US disclosed
US-20100286114-A1 HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF SIENA BIOTECH S.P.A. (IT) 2010-11-11 — — US disclosed
EP-2227456-A2 HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF Siena Biotech S.p.A. (IT) 2010-09-15 — — EP disclosed
US-20100145054-A1 IMIDAZOLE DERIVATIVES HAVING ARYL PIPERIDINE SUBSTITUENT, METHOD FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-06-10 — — US disclosed
WO-2009074300-A2 HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF SIENA BIOTECH S.P.A. (IT) 2009-06-18 — — WO disclosed
WO-2009074300-A2 HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF SIENA BIOTECH S.P.A. (IT) 2009-06-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088752-A1 HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF SHH, GLI1, SMO KDM4E 3170/4885NPC1 380/4885RAB9A 1078/4885
US-20100286114-A1 HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF SHH, GLI1, SMO KDM4E 3170/4885NPC1 380/4885RAB9A 1078/4885
US-20100145054-A1 IMIDAZOLE DERIVATIVES HAVING ARYL PIPERIDINE SUBSTITUENT, METHOD FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME TYR, MCHR1, MCHR2 KDM4E 220/4885NPC1 223/4885RAB9A 687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.